Boehringer Ingelheim Pharma GmbH & Co. KG, Baden-Wurttemberg, Germany
Roman studied Pharmaceutical Sciences at the University of Freiburg, Germany, and graduated after a research stay at the University of East Anglia, UK, in 2015. During his doctoral studies in the group of Prof. Manfred Jung, University of Freiburg, Germany, he developed in vitro assay systems and chemical probes for the screening and characterization of novel small molecule inhibitors of epigenetic targets with special focus on lysine acetyltransferases. In 2019, he obtained his Ph.D. in Pharmaceutical and Medicinal Chemistry from the Albert-Ludwigs-University in Freiburg, Germany. Subsequently, he started his postdoctoral work in the High-Throughput Biology group at Boehringer Ingelheim Pharma GmbH & Co.KG in Biberach, Germany, where he was responsible for the establishment and technological advancement of MS-based technologies to enable label-free high-throughput screening and to provide insights into drug-protein interactions beyond the generic potency readout. Since November 2021, Roman continues his work with Boehringer Ingelheim as a Scientist within the department of Drug Discovery Sciences.
Disclosure information not submitted.
Monday, February 7, 2022
2:00 PM – 2:30 PM